Prof. Dr. Beat Thürlimann
Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply.
Huober J, Thürlimann B, Dietrich D. Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply. JAMA Oncol 2024
Feb 8, 2024Is Pertuzumab Plus Trastuzumab Without Chemotherapy a Reasonable Treatment for ERBB2-Positive Metastatic Breast Cancer?-Reply.
Feb 8, 2024JAMA Oncol 2024
Huober Jens, Thürlimann Beat, Dietrich Daniel
Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Huober J, Weder P, Ribi K, Thürlimann B, Thery J, Li Q, Vanlemmens L, Guiu S, Brain E, Grenier J, Dalenc F, Levy C, Savoye A, Müller A, Membrez-Antonioli V, Gerard M, Lemonnier J, Hawle H, Dietrich D, Boven E, Bonnefoi H, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group. Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA Oncol 2023
Aug 10, 2023Pertuzumab Plus Trastuzumab With or Without Chemotherapy Followed by Emtansine in ERBB2-Positive Metastatic Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Aug 10, 2023JAMA Oncol 2023
Huober Jens, Weder Patrik, Ribi Karin, Thürlimann Beat, Thery Jean-Christophe, Li Qiyu, Vanlemmens Laurence, Guiu Séverine, Brain Etienne, Grenier Julien, Dalenc Florence, Levy Christelle, Savoye Aude-Marie, Müller Andreas S, Membrez-Antonioli Véronique, Gerard Marie-Aline, Lemonnier Jérôme, Hawle Hanne, Dietrich Daniel, Boven Epie, Bonnefoi Hervé R, Swiss Group for Clinical Cancer Research, Unicancer Breast Group, and Dutch Breast Cancer Research Group
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Luen S, Viale G, Nik-Zainal S, Savas P, Kammler R, Dell'Orto P, Biasi O, Degasperi A, Brown L, Láng I, MacGrogan G, Tondini C, Bellet M, Villa F, Bernardo A, Ciruelos E, Karlsson P, Neven P, Climent M, Müller-Hübenthal B, Jochum W, Bonnefoi H, Martino S, Davidson N, Geyer C, Chia S, Ingle J, Coleman R, Solbach C, Thürlimann B, Colleoni M, Coates A, Goldhirsch A, Fleming G, Francis P, Speed T, Regan M, Loi S. Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. Ann Oncol 2023; 34:397-409.
Jan 25, 2023Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Jan 25, 2023Ann Oncol 2023; 34:397-409
Luen Stephen J, Viale Giuseppe, Nik-Zainal S, Savas Peter, Kammler Roswitha, Dell'Orto Patrizia, Biasi Olivia Maria, Degasperi A, Brown Louise C, Láng István, MacGrogan Gaëtan, Tondini Carlo, Bellet Meritxell, Villa F, Bernardo A, Ciruelos Eva, Karlsson Per, Neven Patrick, Climent Miguel A, Müller-Hübenthal Boris, Jochum Wolfram, Bonnefoi Hervé R, Martino Silvana, Davidson Nancy E, Geyer Charles E, Chia S K, Ingle James N, Coleman Robert E, Solbach Christine, Thürlimann Beat, Colleoni Marco, Coates Alan S, Goldhirsch Aron, Fleming Gini F, Francis Prudence A, Speed T P, Regan Meredith M, Loi Sherene
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Burstein H, Gnant M, Winer E, Senn H, Regan M, Poortmans P, Weber W, Thürlimann B, Curigliano G, Panelists of the St Gallen Consensus Conference. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol 2021; 32:1216-1235.
Jul 6, 2021Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021
Jul 6, 2021Ann Oncol 2021; 32:1216-1235
Burstein H J, Gnant M, Winer E P, Senn H J, Regan M M, Poortmans P, Weber W P, Thürlimann Beat, Curigliano G, Panelists of the St Gallen Consensus Conference
Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects
Herrmann C, Morant R, Walser E, Mousavi M, Thürlimann B. Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects. BMC cancer 2021; 21:229.
Mar 6, 2021Screening is associated with lower mastectomy rates in eastern Switzerland beyond stage effects
Mar 6, 2021BMC cancer 2021; 21:229
Herrmann Christian, Morant Rudolf, Walser Esther, Mousavi Mohsen, Thürlimann Beat
Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Stoffel S, Lupatsch J, Schwenkglenks M, Dietrich D, Schär C, Feller A, Anchisi S, von Briel T, Zürrer-Härdi U, Gillessen S, Cathomas R, Thürlimann B, von Moos R, Mark M. Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study. Swiss Med Wkly 2021; 151:w20464.
Mar 1, 2021Patterns of care and economic consequences of using bone-targeted agents for castration-sensitive prostate cancer patients with bone metastases to prevent skeletal-related events in Switzerland - the SAKK 95/16 prostate study
Mar 1, 2021Swiss Med Wkly 2021; 151:w20464
Stoffel Sandro Tiziano, Lupatsch Judith E, Schwenkglenks Matthias, Dietrich Daniel, Schär Corinne, Feller Anita, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Gillessen Silke, Cathomas Richard, Thürlimann Beat, von Moos Roger, Mark Michael Thomas
Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Ribi K, von Moos R, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Thürlimann B, Mark M. Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16). BMC cancer 2021; 21:182.
Feb 19, 2021Quality of life and pain in patients with metastatic bone disease from solid tumors treated with bone-targeted agents- a real-world cross-sectional study from Switzerland (SAKK 95/16)
Feb 19, 2021BMC cancer 2021; 21:182
Ribi Karin, von Moos Roger, Caspar Clemens B, Mannhart Meinrad, von Burg Philippe, Blum Veronika, Bohanes Pierre, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Cathomas Richard, Dietrich Daniel, Schär Corinne, Thürlimann Beat, Mark Michael
Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
Leone J, Vaz-Luis I, Colleoni M, Di Leo A, Goldhirsch A, Wardley A, Bonnefoi H, Láng I, Neven P, Harvey V, Ejlertsen B, Gelber R, Giobbie-Hurder A, Rabaglio M, Coates A, Thürlimann B, Regan M, Cole B, Lin N. Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial. Cancer 2020
Dec 8, 2020Clinical behavior of recurrent hormone receptor-positive breast cancer by adjuvant endocrine therapy within the Breast International Group 1-98 clinical trial
Dec 8, 2020Cancer 2020
Leone Jose P, Vaz-Luis Ines, Colleoni Marco, Di Leo Angelo, Goldhirsch Aron, Wardley Andrew, Bonnefoi Hervé, Láng István, Neven Patrick, Harvey Vernon J, Ejlertsen Bent, Gelber Richard D, Giobbie-Hurder Anita, Rabaglio Manuela, Coates Alan S, Thürlimann Beat, Regan Meredith M, Cole Bernard F, Lin Nancy U
Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Rabaglio M, Thürlimann B, Colleoni M, Goldhirsch A, Gelber R, Coates A, Castiglione M, Ruepp B, Wardley A, Bonnefoi H, Láng I, Neven P, Harvey V, Ejlertsen B, Giobbie-Hurder A, Maibach R, Sun Z, Regan M. Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial. Breast Cancer Res Treat 2020
Nov 7, 2020Cumulative incidence of cardiovascular events under tamoxifen and letrozole alone and in sequence: a report from the BIG 1-98 trial
Nov 7, 2020Breast Cancer Res Treat 2020
Rabaglio Manuela, Thürlimann Beat, Colleoni Marco, Goldhirsch Aron, Gelber Richard D, Coates Alan S, Castiglione Monica, Ruepp Barbara, Wardley Andrew, Bonnefoi Hervé, Láng István, Neven Patrick, Harvey Vernon J, Ejlertsen Bent, Giobbie-Hurder Anita, Maibach Rudolf, Sun Zhuoxin, Regan Meredith M
Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
Luen S, Regan M, Colleoni M, Di Leo A, Viale G, Thürlimann B, Hackl W, Demanse D, Biasi O, Dell'orto P, Kammler R, Savas P, Lee C, Asher R, Loi S. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. Ann Oncol 2020; 31:1359-1365.
Jul 8, 2020Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study
Jul 8, 2020Ann Oncol 2020; 31:1359-1365
Luen S J, Regan M M, Colleoni M, Di Leo A, Viale G, Thürlimann Beat, Hackl W, Demanse D, Biasi O M, Dell'orto P, Kammler R, Savas P, Lee C K, Asher R, Loi S
Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
Maranta A, Broder S, Fritzsche C, Knauer M, Thürlimann B, Jochum W, Ruhstaller T. Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. Breast 2020; 51:120-126.
Mar 23, 2020Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution's Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer
Mar 23, 2020Breast 2020; 51:120-126
Maranta Angela Fischer, Broder Simon, Fritzsche Constanze, Knauer Michael, Thürlimann Beat, Jochum Wolfram, Ruhstaller Thomas
Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
Eppenberger-Castori S, Klingbiel D, Ruhstaller T, Dietrich D, Rufle D, Rothgiesser K, Pagani O, Thürlimann B. Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99. BMC cancer 2020; 20:114.
Feb 11, 2020Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99
Feb 11, 2020BMC cancer 2020; 20:114
Eppenberger-Castori Serenella, Klingbiel Dirk, Ruhstaller Thomas, Dietrich Daniel, Rufle Daniel Alexander, Rothgiesser Karin, Pagani Olivia, Thürlimann Beat
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Burstein H, Thürlimann B, Winer E, Senn H, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsky P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019; 30:1541-1557.
Dec 27, 2019Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Dec 27, 2019Ann Oncol 2019; 30:1541-1557
Burstein H J, Thürlimann Beat, Winer E P, Senn H-J, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsky P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019
Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Mark M, Caspar C, Mannhart M, von Burg P, Blum V, Bohanes P, Anchisi S, von Briel T, Zürrer-Härdi U, Cathomas R, Dietrich D, Schär C, Ribi K, Thürlimann B, von Moos R. Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16). J Bone Oncol 2019; 21:100273.
Dec 16, 2019Patterns of care for patients with metastatic bone disease in solid tumors: A cross-sectional study from Switzerland (SAKK 95/16)
Dec 16, 2019J Bone Oncol 2019; 21:100273
Mark Michael, Caspar Clemens B, Mannhart Meinrad, von Burg Philipp, Blum Veronika, Bohanes Pierre, Anchisi Sandro, von Briel Thomas, Zürrer-Härdi Ursina, Cathomas Richard, Dietrich Daniel, Schär Corinne, Ribi Karin, Thürlimann Beat, von Moos Roger
Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017"
Curigliano G, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". Ann Oncol 2019; 30:1181.
Dec 4, 2019Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017"
Dec 4, 2019Ann Oncol 2019; 30:1181
Curigliano G, Thürlimann Beat, Senn H-J, Piccart-Gebhart M, Regan M M, Colleoni M, Loibl S, Dubsky P, Gnant M, P Winer E, Burstein H J, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017
Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
Coates A, Goldhirsch A, Gelber R, Ingle J, Thürlimann B, Senn H. Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?. Ann Oncol 2019; 20:1751-1752.
Dec 4, 2019Reply to Does the expert panel at the St Gallen meeting provide an unbiased opinion about the management of women with early breast cancer?
Dec 4, 2019Ann Oncol 2019; 20:1751-1752
Coates A S, Goldhirsch A, Gelber R D, Ingle J N, Thürlimann Beat, Senn H-J
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Burstein H, Thürlimann B, Winer E, Senn H, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsky P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol 2019; 30:1541-1557.
Oct 1, 2019Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
Oct 1, 2019Ann Oncol 2019; 30:1541-1557
Burstein H J, Thürlimann Beat, Winer E P, Senn H-J, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsky P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019
Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
Varga Z, Thürlimann B, Klingbiel D, Hawle H, Tille J, Rau T, Perriard U, Jochum W, Li Q, Ruhstaller T. Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Sci Rep 2019; 9:13534.
Sep 19, 2019Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort
Sep 19, 2019Sci Rep 2019; 9:13534
Varga Zsuzsanna, Thürlimann Beat, Klingbiel Dirk, Hawle Hanne, Tille Jean-Christoph, Rau Tilman, Perriard Ulrike, Jochum Wolfram, Li Qiyu, Ruhstaller Thomas
Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Schmid S, Zaman K, Weder P, von Moos R, Thürlimann B, Rochlitz C, Pestalozzi B, Pagani O, Oehlschlegel C, Nolè F, Munzone E, Mamot C, Goldhirsch A, Aebi S, Klingbiel D, Ruhstaller T. Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data. BMC cancer 2019; 19:902.
Sep 10, 2019Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data
Sep 10, 2019BMC cancer 2019; 19:902
Schmid Sabine, Zaman Khalil, Weder Patrik, von Moos Roger, Thürlimann Beat, Rochlitz Christoph, Pestalozzi Bernhard, Pagani Olivia, Oehlschlegel Christian, Nolè Franco, Munzone Elisabetta, Mamot Christoph, Goldhirsch Aron, Aebi Stefan, Klingbiel Dirk, Ruhstaller Thomas
Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer
Buechler S, Badve S, Leyland-Jones B, Viale G, Kammler R, Thürlimann B, Willis S, Gökmen-Polar Y, Gray K, Regan M. Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer. JNCI Cancer Spectr 2019; 3:pkz051.
Aug 16, 2019Independent Validation of EarlyR Gene Signature in BIG 1-98: A Randomized, Double-Blind, Phase III Trial Comparing Letrozole and Tamoxifen as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive, Early Breast Cancer
Aug 16, 2019JNCI Cancer Spectr 2019; 3:pkz051
Buechler Steven A, Badve Sunil S, Leyland-Jones Brian, Viale Giuseppe, Kammler Rosita, Thürlimann Beat, Willis Scooter, Gökmen-Polar Yesim, Gray Kathryn P, Regan Meredith M